Clinical Trial Update: Valganciclovir to Reduce T Cell Activation in HIV Infection [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating valganciclovir to reduce T cell activation in HIV infection has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections
• HIV Infections

Drugs mentioned

• Valganciclovir (Valganciclovir)

Snippet

Sponsor: University of California, San Francisco | Conditions: HIV Infections, Cytomegalovirus Infections | Phase 4 | Status: COMPLETED | Results posted: 2013-11-08